The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

Spravato is a first-of-its-kind medication to help manage treatment-resistant depression, according to Johnson & Johnson.

They are now the most commonly prescribed antidepressant medications. They are prescribed to treat depression but are also used to treat a broader range of depressive disorders, anxiety disorders, and ...

But many people who take daily medications are unaware that certain drugs in their pill box can also increase their risk of ...

Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

It's become increasingly clear that the gut microbiome can affect human health, including mental health. Which bacterial ...

Healthcare professionals may recommend tapering off antidepressants, like Lexapro, if you experience unwanted side effects, need to switch medications, or have reached the end of a short-term ...

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower ...

Stimulant medications are considered the first-line treatment for ADHD for some very good reasons. Here are 6 things to know about stimulant medications in ADHD.